Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 30.9
(0.65%)
TWD 30.9
(0.65%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 375.17 Million TWD | 128.52% |
| 2022 | 164.17 Million TWD | 180.1% |
| 2021 | -204.95 Million TWD | -18.78% |
| 2020 | -172.55 Million TWD | -16.66% |
| 2019 | -147.92 Million TWD | -1783.8% |
| 2018 | 8.78 Million TWD | -76.08% |
| 2017 | 36.72 Million TWD | 121.98% |
| 2016 | 16.54 Million TWD | 18.59% |
| 2015 | 13.95 Million TWD | -91.46% |
| 2014 | 163.39 Million TWD | -45.66% |
| 2013 | 300.69 Million TWD | 147.88% |
| 2012 | 121.3 Million TWD | 67.94% |
| 2011 | 72.22 Million TWD | -34.89% |
| 2010 | 110.93 Million TWD | -15.34% |
| 2009 | 131.03 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 64.93 Million TWD | -41.17% |
| 2024 Q1 | 110.37 Million TWD | 0.48% |
| 2023 FY | 375.17 Million TWD | 128.52% |
| 2023 Q1 | 80.11 Million TWD | 495.01% |
| 2023 Q2 | 109.04 Million TWD | 36.11% |
| 2023 Q3 | 76.16 Million TWD | -30.15% |
| 2023 Q4 | 109.84 Million TWD | 44.23% |
| 2022 Q3 | 68.07 Million TWD | -21.93% |
| 2022 Q1 | 44.82 Million TWD | 398.14% |
| 2022 FY | 164.17 Million TWD | 180.1% |
| 2022 Q4 | -20.28 Million TWD | -129.79% |
| 2022 Q2 | 87.2 Million TWD | 94.53% |
| 2021 Q4 | -15.03 Million TWD | 55.03% |
| 2021 Q3 | -33.43 Million TWD | -730.21% |
| 2021 FY | -204.95 Million TWD | -18.78% |
| 2021 Q1 | 5.03 Million TWD | 109.31% |
| 2021 Q2 | 5.3 Million TWD | 5.4% |
| 2020 Q4 | -54.05 Million TWD | -453.58% |
| 2020 Q1 | 26.77 Million TWD | -23.0% |
| 2020 Q2 | 8.54 Million TWD | -68.1% |
| 2020 FY | -172.55 Million TWD | -16.66% |
| 2020 Q3 | -9.76 Million TWD | -214.33% |
| 2019 Q4 | 34.76 Million TWD | 441.47% |
| 2019 Q3 | -10.18 Million TWD | 59.14% |
| 2019 FY | -147.92 Million TWD | -1783.8% |
| 2019 Q1 | 14.29 Million TWD | 85.01% |
| 2019 Q2 | -24.91 Million TWD | -274.34% |
| 2018 FY | 8.78 Million TWD | -76.08% |
| 2018 Q2 | -1.32 Million TWD | -107.9% |
| 2018 Q1 | 16.75 Million TWD | -24.65% |
| 2018 Q4 | 7.72 Million TWD | 153.76% |
| 2018 Q3 | -14.36 Million TWD | -985.27% |
| 2017 Q1 | -8.82 Million TWD | -121.19% |
| 2017 Q4 | 22.23 Million TWD | 58.68% |
| 2017 Q3 | 14.01 Million TWD | 50.53% |
| 2017 FY | 36.72 Million TWD | 121.98% |
| 2017 Q2 | 9.3 Million TWD | 205.46% |
| 2016 Q3 | -6.19 Million TWD | -149.46% |
| 2016 FY | 16.54 Million TWD | 18.59% |
| 2016 Q4 | 41.65 Million TWD | 772.54% |
| 2016 Q2 | -2.48 Million TWD | 84.89% |
| 2016 Q1 | -16.43 Million TWD | -124.62% |
| 2015 FY | 13.95 Million TWD | -91.46% |
| 2015 Q1 | -26.34 Million TWD | -148.5% |
| 2015 Q2 | -9.7 Million TWD | 63.16% |
| 2015 Q4 | 66.76 Million TWD | 498.24% |
| 2015 Q3 | -16.76 Million TWD | -72.75% |
| 2014 Q4 | 54.31 Million TWD | 347.95% |
| 2014 Q2 | 70.07 Million TWD | 15.04% |
| 2014 Q1 | 60.91 Million TWD | 86.9% |
| 2014 FY | 163.39 Million TWD | -45.66% |
| 2014 Q3 | -21.9 Million TWD | -131.26% |
| 2013 Q1 | 120.34 Million TWD | 1705.94% |
| 2013 Q3 | 89.1 Million TWD | 51.93% |
| 2013 Q4 | 32.59 Million TWD | -63.43% |
| 2013 FY | 300.69 Million TWD | 147.88% |
| 2013 Q2 | 58.64 Million TWD | -51.27% |
| 2012 Q4 | 6.66 Million TWD | -88.33% |
| 2012 Q3 | 57.08 Million TWD | 50.77% |
| 2012 FY | 121.3 Million TWD | 67.94% |
| 2012 Q2 | 37.86 Million TWD | 65.52% |
| 2012 Q1 | 22.87 Million TWD | 49.88% |
| 2011 Q2 | 20.34 Million TWD | -11.62% |
| 2011 Q1 | 23.01 Million TWD | 0.89% |
| 2011 Q3 | 13.61 Million TWD | -33.07% |
| 2011 Q4 | 15.26 Million TWD | 12.11% |
| 2011 FY | 72.22 Million TWD | -34.89% |
| 2010 Q3 | 13.26 Million TWD | -66.63% |
| 2010 FY | 110.93 Million TWD | -15.34% |
| 2010 Q1 | 35.1 Million TWD | 0.0% |
| 2010 Q4 | 22.81 Million TWD | 71.98% |
| 2010 Q2 | 39.75 Million TWD | 13.25% |
| 2009 FY | 131.03 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Apex Biotechnology Corp. | 115.78 Million TWD | -224.029% |
| Panion & Bf Biotech Inc. | 77.21 Million TWD | -385.852% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 264.9 Million TWD | -41.622% |
| GenMont Biotech Incorporation | 32.99 Million TWD | -1037.189% |
| Abnova (Taiwan) Corporation | 43.67 Million TWD | -758.945% |
| Adimmune Corporation | -639.89 Million TWD | 158.63% |
| Tanvex BioPharma, Inc. | -2.13 Billion TWD | 117.555% |
| Polaris Group | -1.57 Billion TWD | 123.795% |
| Energenesis Biomedical CO.,LTD. | -260.38 Million TWD | 244.084% |
| UnicoCell Biomed Co., Ltd. | -84.1 Million TWD | 546.057% |
| PELL Bio-Med Technology Co. Ltd. | -398.75 Million TWD | 194.085% |